Beta2-adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men

Morten Hostrup; Søren Reitelseder; Søren Jessen; Anders Kalsen; Michael Permin Nyberg; Jon Egelund; Michael Kreiberg; Caroline Maag Kristensen; Martin Thomassen; Henriette Pilegaard; Vibeke Backer; Glenn A Jacobson; Lars Holm; Jens Bangsbo

doi:10.1113/jp275560

Beta₂-adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men

Morten Hostrup^*, Søren Reitelseder, Søren Jessen, Anders Kalsen, Michael Permin Nyberg, Jon Egelund, Michael Kreiberg, Caroline Maag Kristensen, Martin Thomassen, Henriette Pilegaard, Vibeke Backer, Glenn A Jacobson, Lars Holm, Jens Bangsbo

^*Corresponding author for this work

18 Citations (Scopus)

Abstract

Key points: Animal models have shown that beta₂-adrenoceptor stimulation increases protein synthesis and attenuates breakdown processes in skeletal muscle. Thus, the beta₂-adrenoceptor is a potential target in the treatment of disuse-, disease- and age-related muscle atrophy. In the present study, we show that a few days of oral treatment with the commonly prescribed beta₂-adrenoceptor agonist, salbutamol, increased skeletal muscle protein synthesis and breakdown during the first 5 h after resistance exercise in young men. Salbutamol also counteracted a negative net protein balance in skeletal muscle after resistance exercise. Changes in protein turnover rates induced by salbutamol were associated with protein kinase A-signalling, activation of Akt2 and modulation of mRNA levels of growth-regulating proteins in skeletal muscle. These findings indicate that protein turnover rates can be augmented by beta₂-adrenoceptor agonist treatment during recovery from resistance exercise in humans. Abstract: The effect of beta₂-adrenoceptor stimulation on skeletal muscle protein turnover and intracellular signalling is insufficiently explored in humans, particularly in association with exercise. In a randomized, placebo-controlled, cross-over study investigating 12 trained men, the effects of beta₂-agonist (6 × 4 mg oral salbutamol) on protein turnover rates, intracellular signalling and mRNA response in skeletal muscle were investigated 0.5–5 h after quadriceps resistance exercise. Each trial was preceded by a 4-day lead-in treatment period. Leg protein turnover rates were assessed by infusion of [¹³C₆]-phenylalanine and sampling of arterial and venous blood, as well as vastus lateralis muscle biopsies 0.5 and 5 h after exercise. Furthermore, myofibrillar fractional synthesis rate, intracellular signalling and mRNA response were measured in muscle biopsies. The mean (95% confidence interval) myofibrillar fractional synthesis rate was higher for salbutamol than placebo [0.079 (95% CI, 0.064 to 0.093) vs. 0.066 (95% CI, 0.056 to 0.075%) × h⁻¹] (P < 0.05). Mean net leg phenylalanine balance 0.5–5 h after exercise was higher for salbutamol than placebo [3.6 (95% CI, 1.0 to 6.2 nmol) × min⁻¹ × 100 g_{Leg Lean Mass} ⁻¹] (P < 0.01). Phosphorylation of Akt2, cAMP response element binding protein and PKA substrate 0.5 and 5 h after exercise, as well as phosphorylation of eEF2 5 h after exercise, was higher (P < 0.05) for salbutamol than placebo. Calpain-1, Forkhead box protein O1, myostatin and Smad3 mRNA content was higher (P < 0.01) for salbutamol than placebo 0.5 h after exercise, as well as Forkhead box protein O1 and myostatin mRNA content 5 h after exercise, whereas ActivinRIIB mRNA content was lower (P < 0.01) for salbutamol 5 h after exercise. These observations suggest that beta₂-agonist increases protein turnover rates in skeletal muscle after resistance exercise in humans, with concomitant cAMP/PKA and Akt2 signalling, as well as modulation of mRNA response of growth-regulating proteins.

Original language	English
Journal	Journal of Physiology
Volume	596
Issue number	17
Pages (from-to)	4121-4139
Number of pages	19
ISSN	0022-3751
DOIs	https://doi.org/10.1113/jp275560
Publication status	Published - 1 Sept 2018

Keywords

Adrenergic
Adrenoceptor
Albuterol
Beta-agonists
Doping
Hypertrophy
LABA
Metabolism
SABA
Strength
Training

Access to Document

10.1113/jp275560

JP275560Final published version, 1.62 MB

Cite this

Hostrup, M., Reitelseder, S., Jessen, S., Kalsen, A., Nyberg, M. P., Egelund, J., Kreiberg, M., Maag Kristensen, C., Thomassen, M., Pilegaard, H., Backer, V., Jacobson, G. A., Holm, L., & Bangsbo, J. (2018). Beta₂-adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men. Journal of Physiology, 596(17), 4121-4139. https://doi.org/10.1113/jp275560

Beta₂-adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men. / Hostrup, Morten; Reitelseder, Søren; Jessen, Søren et al.

In: Journal of Physiology, Vol. 596, No. 17, 01.09.2018, p. 4121-4139.

Research output: Contribution to journal › Journal article › Research › peer-review

Hostrup, M, Reitelseder, S, Jessen, S, Kalsen, A, Nyberg, MP, Egelund, J, Kreiberg, M, Maag Kristensen, C, Thomassen, M , Pilegaard, H , Backer, V, Jacobson, GA, Holm, L & Bangsbo, J 2018, 'Beta₂-adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men', Journal of Physiology, vol. 596, no. 17, pp. 4121-4139. https://doi.org/10.1113/jp275560

@article{794c87fa1ca64e4fa08cebcc95c79b2c,

title = "Beta2-adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men",

abstract = "Key points: Animal models have shown that beta2-adrenoceptor stimulation increases protein synthesis and attenuates breakdown processes in skeletal muscle. Thus, the beta2-adrenoceptor is a potential target in the treatment of disuse-, disease- and age-related muscle atrophy. In the present study, we show that a few days of oral treatment with the commonly prescribed beta2-adrenoceptor agonist, salbutamol, increased skeletal muscle protein synthesis and breakdown during the first 5 h after resistance exercise in young men. Salbutamol also counteracted a negative net protein balance in skeletal muscle after resistance exercise. Changes in protein turnover rates induced by salbutamol were associated with protein kinase A-signalling, activation of Akt2 and modulation of mRNA levels of growth-regulating proteins in skeletal muscle. These findings indicate that protein turnover rates can be augmented by beta2-adrenoceptor agonist treatment during recovery from resistance exercise in humans. Abstract: The effect of beta2-adrenoceptor stimulation on skeletal muscle protein turnover and intracellular signalling is insufficiently explored in humans, particularly in association with exercise. In a randomized, placebo-controlled, cross-over study investigating 12 trained men, the effects of beta2-agonist (6 × 4 mg oral salbutamol) on protein turnover rates, intracellular signalling and mRNA response in skeletal muscle were investigated 0.5–5 h after quadriceps resistance exercise. Each trial was preceded by a 4-day lead-in treatment period. Leg protein turnover rates were assessed by infusion of [13C6]-phenylalanine and sampling of arterial and venous blood, as well as vastus lateralis muscle biopsies 0.5 and 5 h after exercise. Furthermore, myofibrillar fractional synthesis rate, intracellular signalling and mRNA response were measured in muscle biopsies. The mean (95% confidence interval) myofibrillar fractional synthesis rate was higher for salbutamol than placebo [0.079 (95% CI, 0.064 to 0.093) vs. 0.066 (95% CI, 0.056 to 0.075%) × h−1] (P < 0.05). Mean net leg phenylalanine balance 0.5–5 h after exercise was higher for salbutamol than placebo [3.6 (95% CI, 1.0 to 6.2 nmol) × min−1 × 100 gLeg Lean Mass −1] (P < 0.01). Phosphorylation of Akt2, cAMP response element binding protein and PKA substrate 0.5 and 5 h after exercise, as well as phosphorylation of eEF2 5 h after exercise, was higher (P < 0.05) for salbutamol than placebo. Calpain-1, Forkhead box protein O1, myostatin and Smad3 mRNA content was higher (P < 0.01) for salbutamol than placebo 0.5 h after exercise, as well as Forkhead box protein O1 and myostatin mRNA content 5 h after exercise, whereas ActivinRIIB mRNA content was lower (P < 0.01) for salbutamol 5 h after exercise. These observations suggest that beta2-agonist increases protein turnover rates in skeletal muscle after resistance exercise in humans, with concomitant cAMP/PKA and Akt2 signalling, as well as modulation of mRNA response of growth-regulating proteins.",

keywords = "Adrenergic, Adrenoceptor, Albuterol, Beta-agonists, Doping, Hypertrophy, LABA, Metabolism, SABA, Strength, Training",

author = "Morten Hostrup and S{\o}ren Reitelseder and S{\o}ren Jessen and Anders Kalsen and Nyberg, {Michael Permin} and Jon Egelund and Michael Kreiberg and {Maag Kristensen}, Caroline and Martin Thomassen and Henriette Pilegaard and Vibeke Backer and Jacobson, {Glenn A} and Lars Holm and Jens Bangsbo",

note = "CURIS 2018 NEXS 268",

year = "2018",

month = sep,

day = "1",

doi = "10.1113/jp275560",

language = "English",

volume = "596",

pages = "4121--4139",

journal = "The Journal of Physiology",

issn = "0022-3751",

publisher = "Wiley-Blackwell",

number = "17",

}

TY - JOUR

T1 - Beta2-adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men

AU - Hostrup, Morten

AU - Reitelseder, Søren

AU - Jessen, Søren

AU - Kalsen, Anders

AU - Nyberg, Michael Permin

AU - Egelund, Jon

AU - Kreiberg, Michael

AU - Maag Kristensen, Caroline

AU - Thomassen, Martin

AU - Pilegaard, Henriette

AU - Backer, Vibeke

AU - Jacobson, Glenn A

AU - Holm, Lars

AU - Bangsbo, Jens

N1 - CURIS 2018 NEXS 268

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Key points: Animal models have shown that beta2-adrenoceptor stimulation increases protein synthesis and attenuates breakdown processes in skeletal muscle. Thus, the beta2-adrenoceptor is a potential target in the treatment of disuse-, disease- and age-related muscle atrophy. In the present study, we show that a few days of oral treatment with the commonly prescribed beta2-adrenoceptor agonist, salbutamol, increased skeletal muscle protein synthesis and breakdown during the first 5 h after resistance exercise in young men. Salbutamol also counteracted a negative net protein balance in skeletal muscle after resistance exercise. Changes in protein turnover rates induced by salbutamol were associated with protein kinase A-signalling, activation of Akt2 and modulation of mRNA levels of growth-regulating proteins in skeletal muscle. These findings indicate that protein turnover rates can be augmented by beta2-adrenoceptor agonist treatment during recovery from resistance exercise in humans. Abstract: The effect of beta2-adrenoceptor stimulation on skeletal muscle protein turnover and intracellular signalling is insufficiently explored in humans, particularly in association with exercise. In a randomized, placebo-controlled, cross-over study investigating 12 trained men, the effects of beta2-agonist (6 × 4 mg oral salbutamol) on protein turnover rates, intracellular signalling and mRNA response in skeletal muscle were investigated 0.5–5 h after quadriceps resistance exercise. Each trial was preceded by a 4-day lead-in treatment period. Leg protein turnover rates were assessed by infusion of [13C6]-phenylalanine and sampling of arterial and venous blood, as well as vastus lateralis muscle biopsies 0.5 and 5 h after exercise. Furthermore, myofibrillar fractional synthesis rate, intracellular signalling and mRNA response were measured in muscle biopsies. The mean (95% confidence interval) myofibrillar fractional synthesis rate was higher for salbutamol than placebo [0.079 (95% CI, 0.064 to 0.093) vs. 0.066 (95% CI, 0.056 to 0.075%) × h−1] (P < 0.05). Mean net leg phenylalanine balance 0.5–5 h after exercise was higher for salbutamol than placebo [3.6 (95% CI, 1.0 to 6.2 nmol) × min−1 × 100 gLeg Lean Mass −1] (P < 0.01). Phosphorylation of Akt2, cAMP response element binding protein and PKA substrate 0.5 and 5 h after exercise, as well as phosphorylation of eEF2 5 h after exercise, was higher (P < 0.05) for salbutamol than placebo. Calpain-1, Forkhead box protein O1, myostatin and Smad3 mRNA content was higher (P < 0.01) for salbutamol than placebo 0.5 h after exercise, as well as Forkhead box protein O1 and myostatin mRNA content 5 h after exercise, whereas ActivinRIIB mRNA content was lower (P < 0.01) for salbutamol 5 h after exercise. These observations suggest that beta2-agonist increases protein turnover rates in skeletal muscle after resistance exercise in humans, with concomitant cAMP/PKA and Akt2 signalling, as well as modulation of mRNA response of growth-regulating proteins.

AB - Key points: Animal models have shown that beta2-adrenoceptor stimulation increases protein synthesis and attenuates breakdown processes in skeletal muscle. Thus, the beta2-adrenoceptor is a potential target in the treatment of disuse-, disease- and age-related muscle atrophy. In the present study, we show that a few days of oral treatment with the commonly prescribed beta2-adrenoceptor agonist, salbutamol, increased skeletal muscle protein synthesis and breakdown during the first 5 h after resistance exercise in young men. Salbutamol also counteracted a negative net protein balance in skeletal muscle after resistance exercise. Changes in protein turnover rates induced by salbutamol were associated with protein kinase A-signalling, activation of Akt2 and modulation of mRNA levels of growth-regulating proteins in skeletal muscle. These findings indicate that protein turnover rates can be augmented by beta2-adrenoceptor agonist treatment during recovery from resistance exercise in humans. Abstract: The effect of beta2-adrenoceptor stimulation on skeletal muscle protein turnover and intracellular signalling is insufficiently explored in humans, particularly in association with exercise. In a randomized, placebo-controlled, cross-over study investigating 12 trained men, the effects of beta2-agonist (6 × 4 mg oral salbutamol) on protein turnover rates, intracellular signalling and mRNA response in skeletal muscle were investigated 0.5–5 h after quadriceps resistance exercise. Each trial was preceded by a 4-day lead-in treatment period. Leg protein turnover rates were assessed by infusion of [13C6]-phenylalanine and sampling of arterial and venous blood, as well as vastus lateralis muscle biopsies 0.5 and 5 h after exercise. Furthermore, myofibrillar fractional synthesis rate, intracellular signalling and mRNA response were measured in muscle biopsies. The mean (95% confidence interval) myofibrillar fractional synthesis rate was higher for salbutamol than placebo [0.079 (95% CI, 0.064 to 0.093) vs. 0.066 (95% CI, 0.056 to 0.075%) × h−1] (P < 0.05). Mean net leg phenylalanine balance 0.5–5 h after exercise was higher for salbutamol than placebo [3.6 (95% CI, 1.0 to 6.2 nmol) × min−1 × 100 gLeg Lean Mass −1] (P < 0.01). Phosphorylation of Akt2, cAMP response element binding protein and PKA substrate 0.5 and 5 h after exercise, as well as phosphorylation of eEF2 5 h after exercise, was higher (P < 0.05) for salbutamol than placebo. Calpain-1, Forkhead box protein O1, myostatin and Smad3 mRNA content was higher (P < 0.01) for salbutamol than placebo 0.5 h after exercise, as well as Forkhead box protein O1 and myostatin mRNA content 5 h after exercise, whereas ActivinRIIB mRNA content was lower (P < 0.01) for salbutamol 5 h after exercise. These observations suggest that beta2-agonist increases protein turnover rates in skeletal muscle after resistance exercise in humans, with concomitant cAMP/PKA and Akt2 signalling, as well as modulation of mRNA response of growth-regulating proteins.

KW - Adrenergic

KW - Adrenoceptor

KW - Albuterol

KW - Beta-agonists

KW - Doping

KW - Hypertrophy

KW - LABA

KW - Metabolism

KW - SABA

KW - Strength

KW - Training

U2 - 10.1113/jp275560

DO - 10.1113/jp275560

M3 - Journal article

C2 - 29968301

AN - SCOPUS:85051025375

SN - 0022-3751

VL - 596

SP - 4121

EP - 4139

JO - The Journal of Physiology

JF - The Journal of Physiology

IS - 17

ER -